Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 2
2015 3
2016 1
2017 4
2018 2
2019 4
2020 3
2021 8
2022 5
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean connor kearney (23 results)?
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.
Hogg SJ, Motorna O, Cluse LA, Johanson TM, Coughlan HD, Raviram R, Myers RM, Costacurta M, Todorovski I, Pijpers L, Bjelosevic S, Williams T, Huskins SN, Kearney CJ, Devlin JR, Fan Z, Jabbari JS, Martin BP, Fareh M, Kelly MJ, Dupéré-Richer D, Sandow JJ, Feran B, Knight D, Khong T, Spencer A, Harrison SJ, Gregory G, Wickramasinghe VO, Webb AI, Taberlay PC, Bromberg KD, Lai A, Papenfuss AT, Smyth GK, Allan RS, Licht JD, Landau DA, Abdel-Wahab O, Shortt J, Vervoort SJ, Johnstone RW. Hogg SJ, et al. Among authors: kearney cj. Mol Cell. 2021 May 20;81(10):2183-2200.e13. doi: 10.1016/j.molcel.2021.04.015. Mol Cell. 2021. PMID: 34019788 Free PMC article.
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.
Vervoort SJ, Welsh SA, Devlin JR, Barbieri E, Knight DA, Offley S, Bjelosevic S, Costacurta M, Todorovski I, Kearney CJ, Sandow JJ, Fan Z, Blyth B, McLeod V, Vissers JHA, Pavic K, Martin BP, Gregory G, Demosthenous E, Zethoven M, Kong IY, Hawkins ED, Hogg SJ, Kelly MJ, Newbold A, Simpson KJ, Kauko O, Harvey KF, Ohlmeyer M, Westermarck J, Gray N, Gardini A, Johnstone RW. Vervoort SJ, et al. Among authors: kearney cj. Cell. 2021 Jun 10;184(12):3143-3162.e32. doi: 10.1016/j.cell.2021.04.022. Epub 2021 May 17. Cell. 2021. PMID: 34004147 Free PMC article.
Tumor immune evasion arises through loss of TNF sensitivity.
Kearney CJ, Vervoort SJ, Hogg SJ, Ramsbottom KM, Freeman AJ, Lalaoui N, Pijpers L, Michie J, Brown KK, Knight DA, Sutton V, Beavis PA, Voskoboinik I, Darcy PK, Silke J, Trapani JA, Johnstone RW, Oliaro J. Kearney CJ, et al. Sci Immunol. 2018 May 18;3(23):eaar3451. doi: 10.1126/sciimmunol.aar3451. Sci Immunol. 2018. PMID: 29776993
An Inflammatory Perspective on Necroptosis.
Kearney CJ, Martin SJ. Kearney CJ, et al. Mol Cell. 2017 Mar 16;65(6):965-973. doi: 10.1016/j.molcel.2017.02.024. Mol Cell. 2017. PMID: 28306512 Free article. Review.
CRISPR-Cas9 screening identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity.
House IG, Derrick EB, Sek K, Chen AXY, Li J, Lai J, Todd KL, Munoz I, Michie J, Chan CW, Huang YK, Chan JD, Petley EV, Tong J, Nguyen D, Engel S, Savas P, Hogg SJ, Vervoort SJ, Kearney CJ, Burr ML, Lam EYN, Gilan O, Bedoui S, Johnstone RW, Dawson MA, Loi S, Darcy PK, Beavis PA. House IG, et al. Among authors: kearney cj. Cell Rep. 2023 Aug 29;42(8):113014. doi: 10.1016/j.celrep.2023.113014. Epub 2023 Aug 21. Cell Rep. 2023. PMID: 37605534 Free article.
Unleashing TNF cytotoxicity to enhance cancer immunotherapy.
Freeman AJ, Kearney CJ, Silke J, Oliaro J. Freeman AJ, et al. Among authors: kearney cj. Trends Immunol. 2021 Dec;42(12):1128-1142. doi: 10.1016/j.it.2021.10.003. Epub 2021 Nov 6. Trends Immunol. 2021. PMID: 34750058 Review.
BET Inhibition Enhances TNF-Mediated Antitumor Immunity.
Wellinger LC, Hogg SJ, Newman DM, Friess T, Geiss D, Michie J, Ramsbottom KM, Bacac M, Fauti T, Marbach D, Jarassier L, Thienger P, Paehler A, Cluse LA, Kearney CJ, Vervoort SJ, Trapani JA, Oliaro J, Shortt J, Ruefli-Brasse A, Rohle D, Johnstone RW. Wellinger LC, et al. Among authors: kearney cj. Cancer Immunol Res. 2022 Jan;10(1):87-107. doi: 10.1158/2326-6066.CIR-21-0224. Epub 2021 Nov 15. Cancer Immunol Res. 2022. PMID: 34782346
PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity.
Djajawi TM, Pijpers L, Srivaths A, Chisanga D, Chan KF, Hogg SJ, Neil L, Rivera SM, Bartonicek N, Ellis SL, Lim Kam Sian TCC, Faridi P, Liao Y, Pal B, Behren A, Shi W, Vervoort SJ, Johnstone RW, Kearney CJ. Djajawi TM, et al. Among authors: kearney cj. Cell Rep. 2024 Mar 26;43(3):113831. doi: 10.1016/j.celrep.2024.113831. Epub 2024 Feb 23. Cell Rep. 2024. PMID: 38401121 Free article.
Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML.
Salmon JM, Todorovski I, Stanley KL, Bruedigam C, Kearney CJ, Martelotto LG, Rossello F, Semple T, Arnau GM, Zethoven M, Bots M, Bjelosevic S, Cluse LA, Fraser PJ, Litalien V, Vidacs E, McArthur K, Matthews AY, Gressier E, de Weerd NA, Lichte J, Kelly MJ, Hogg SJ, Hertzog PJ, Kats LM, Vervoort SJ, De Carvalho DD, Scheu S, Bedoui S, Kile BT, Lane SW, Perkins AC, Wei AH, Dominguez PM, Johnstone RW. Salmon JM, et al. Among authors: kearney cj. Cancer Discov. 2022 Jun 2;12(6):1560-1579. doi: 10.1158/2159-8290.CD-20-1145. Cancer Discov. 2022. PMID: 35311997 Free PMC article.
37 results